European Neuropsychopharmacology
Volume 20, Issue 5 , Pages 310-316, May 2010

Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST)

  • Wolfgang Gaebel

      Affiliations

    • Department of Psychiatry and Psychotherapy, Heinrich-Heine-University Düsseldorf, Rhineland State Clinics Düsseldorf, Germany
    • Corresponding Author InformationCorresponding author. Department of Psychiatry and Psychotherapy, Heinrich-Heine-University Düsseldorf, Rhineland State Clinics Düsseldorf, Bergische Landstraße 2, D-40629 Düsseldorf, Germany. Tel.: +49 211 922 2000; fax: +49 211 922 2020.
  • ,
  • Mathias Riesbeck

      Affiliations

    • Department of Psychiatry and Psychotherapy, Heinrich-Heine-University Düsseldorf, Rhineland State Clinics Düsseldorf, Germany
  • ,
  • Martina von Wilmsdorff

      Affiliations

    • Department of Psychiatry and Psychotherapy, Heinrich-Heine-University Düsseldorf, Rhineland State Clinics Düsseldorf, Germany
  • ,
  • Tom Burns

      Affiliations

    • Department of Psychiatry, University of Oxford, UK
  • ,
  • Eske M. Derks

      Affiliations

    • Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, The Netherlands
  • ,
  • René S. Kahn

      Affiliations

    • Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, The Netherlands
  • ,
  • Wulf Rössler

      Affiliations

    • Psychiatric University Hospital Zurich, Switzerland
  • ,
  • W. Wolfgang Fleischhacker

      Affiliations

    • Department of Biological Psychiatry, Medical University Innsbruck, Austria
  • ,
  • for the EUFEST Study Group

Received 3 December 2009; received in revised form 14 January 2010; accepted 3 February 2010. published online 04 March 2010.

Abstract 

Effectiveness has become more and more important as a comprehensive outcome measure for (long-term) treatment in schizophrenia. Early predictors to identify patients at a high risk for not succeeding the initiated treatment would be very useful. Discontinuation of the initiated treatment was used as criterion for effectiveness and patients' drug attitude was shown to be predictive for non-adherence or discontinuation of long-term treatment in schizophrenia. Accordingly, the predictive validity of the Drug Attitude Inventory (DAI) for effectiveness should be evaluated. Based on a sub-sample of patients from the EUFEST study for whom DAI assessments were available significant predictors for effectiveness as measured by discontinuation of initiated treatment were identified based on a logistic and a Cox-regression analysis. A Receiver-Operating Characteristic- (ROC-) analysis was conducted for the DAI, prognostic / diagnostic parameters (sensitivity, specificity) were calculated and a cut-off value suggested. In a sample of 228 first-episode patients, the DAI score was the most powerful predictor for effectiveness (p<0.001) besides two other significant predictors (PANSS-positive score and sexual side effects). The ROC-analysis revealed an area under the curve of 0.64 (p<0.001). The suggested cut-off point of about 20 yielded a sensitivity of 70–75% and a specificity of 40–45%. Study results indicate that the Drug Attitude Inventory, filled in by patients early in treatment seems to be a valid predictor for effectiveness as measured by discontinuation of the initiated treatment. DAI scores could also serve as an (differential) indicator for the need of enhanced treatment monitoring. These findings have to be validated in other (first-episode) samples.

Keywords: Schizophrenia;, First episode;, Effectiveness;, Treatment discontinuation;, Drug attitude;, Predictor

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0924-977X(10)00020-9

doi:10.1016/j.euroneuro.2010.02.001

European Neuropsychopharmacology
Volume 20, Issue 5 , Pages 310-316, May 2010